Global Geriatric Medicines Market 2025–2029: Competitive Insights and Opportunities

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Geriatric Medicines Industry Expected To Reach By 2029, Starting From 2025 Levels?

The geriatric medicines market size has shown rapid expansion in recent years. This market is expected to grow from $1227.91 billion in 2024 to $1427.01 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.2%. The historical growth of this market can be attributed to factors like the increasing prevalence of stroke, the rising incidence of chronic diseases, a growing prevalence of cardiovascular diseases, increased government support, and an enhanced emphasis on personalized medicine.

The geriatric medicines market is projected to experience substantial expansion in the coming years. By 2029, its value is forecast to reach $2578.21 billion, exhibiting a compound annual growth rate (CAGR) of 15.9%. This anticipated growth during the forecast period stems from factors such as the growing occurrence of age-related health issues, an expanding elderly demographic, increasing spending on healthcare, a general increase in geriatric medicine, and a rise in hypertension cases. Key trends foreseen over this period encompass the adoption of digital pills and wearable health technology, the creation of methods and tools for secure management of multiple medications, progress in stem cell and gene therapy, wider utilization of telehealth platforms, and improvements in the early detection and prevention of illnesses linked to aging.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20817&type=smp

Which Drivers Are Supporting Growth Of The Geriatric Medicines Market?

The rising occurrence of health issues linked to aging is projected to fuel the expansion of the geriatric medicines market in the future. These age-related health conditions are medical problems that become more frequent or intense with advancing age, stemming from the aging process itself. The primary drivers behind the escalating prevalence of such conditions include longer life expectancies, advancements in healthcare, and an aging population. Geriatric medicines aid in managing age-related health conditions by offering specialized treatments for older adults, thereby enhancing their quality of life and overall healthcare outcomes. For instance, in March 2023, a report issued by the Office for Health Improvement and Disparities (OHID), a UK-based government office, revealed that in 2022, 17.6% of people aged 16 and older reported having a long-term musculoskeletal (MSK) condition, such as arthritis or ongoing issues with their back or joints. This figure represents an increase from the 17.0% prevalence observed in 2021. Consequently, the increasing prevalence of age-related health conditions is a significant driver for the growth of the geriatric medicines market.

What Are The Major Segments Identified In The Geriatric Medicines Market?

The geriatric medicinesmarket covered in this report is segmented –

1) By Therapeutics: Analgesics; Antihypertensive; Statins; Proton Pump Inhibitors; Anticoagulant; Antipsychotic; Other Therapeutics

2) By Condition: Cardiovascular; Arthritis; Neurological; Cancer; Osteoporosis; Respiratory; Other Conditions

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:

1) By Analgesics: Non-Opioid Analgesics (Acetaminophen, NSAIDs); Opioid Analgesics (Morphine, Oxycodone); Topical Analgesics (Lidocaine Patches)

2) By Antihypertensive: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Beta-Blockers; Calcium Channel Blockers; Diuretics; Alpha-Blockers

3) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin; Lovastatin

4) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole

5) By Anticoagulant: Warfarin; Direct Oral Anticoagulants (DOACs): Dabigatran, Rivaroxaban, Apixaban; Heparin

6) By Antipsychotic: Atypical Antipsychotics; Typical Antipsychotics

7) By Other Therapeutics: Antidepressants (SSRIs, SNRIs); Antidiabetic Medications (Insulin, Metformin); Anticonvulsants; Anti-Inflammatory Drugs (Corticosteroids); Cognitive Enhancers (Donepezil, Memantine)

Which Competitive Trends Are Defining The Geriatric Medicines Market Structure?

Leading companies in the geriatric medicines market are concentrating on developing innovative diabetes treatments to address the rising demand for effective solutions among the aging population. Diabetes therapy involves advanced interventions that enhance diabetes management or offer potential cures, surpassing traditional approaches and improving efficacy, safety, and patient outcomes. For instance, in August 2023, Akums Drugs & Pharmaceuticals Ltd., an India-based contract manufacturing pharmaceutical company, announced the introduction of a novel combination therapy featuring Vildagliptin SR and Metformin SR. This sophisticated formulation is specifically designed for the management of Type 2 diabetes in elderly patients. It aims to deliver effective glycemic control, while also minimizing key concerns such as hypoglycemia and weight gain, which are particularly critical for this demographic. By synergizing the mechanisms of both drugs, the combination therapy enhances insulin secretion and effectively reduces blood sugar levels, ensuring both safety and efficacy. The product has secured regulatory approval from the Drug Controller General of India (DCGI).

Which Key Market Players Are Investing In Expansion And Innovation Of Geriatric Medicines Market?

Major companies operating in the geriatric medicines market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Apotex Inc., Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Endo Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/geriatric-medicines-global-market-report

How Do Regional Market Performances Compare Within The Geriatric Medicines Industry?

North America was the largest region in the geriatric medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geriatric medicines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Geriatric Medicines Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20817&type=smp

Browse Through More Reports Similar to the Global Geriatric Medicines Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795